Drug: Axicabtagene ciloleucel (Yescarta, Kite Pharma)
Status: Granted approval for the treatment of adult patients with relapsed or refractory large B-cell lymphoma—including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma—after 2 or more lines of systemic therapy
Axicabtagene ciloleucel is not indicated for the treatment of primary central nervous system